The fragile x syndrome (fxs) treatment market size has grown strongly in recent years. It will grow from $2.07 billion in 2025 to $2.23 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased clinical understanding of fragile x syndrome, expansion of behavioral therapy programs, growing availability of psychiatric medications, rising diagnosis rates of genetic disorders, improved access to specialized care centers.
The fragile x syndrome (fxs) treatment market size is expected to see strong growth in the next few years. It will grow to $3 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing investments in precision medicine research, expansion of gene-targeted therapies, rising clinical trial activity for rare diseases, growing focus on early genetic screening, increasing collaboration between biotech firms and research institutions. Major trends in the forecast period include increasing focus on targeted pharmacological therapies, growing integration of behavioral and drug-based treatments, expansion of personalized treatment approaches, rising adoption of early diagnosis and intervention programs, enhanced development of novel mglur5 and gaba-based therapies.
Government initiatives and funding for rare diseases are expected to drive the expansion of the fragile X syndrome (FXS) treatment market in the near future. Rare diseases are medical conditions that impact a small fraction of the population and are often chronic, progressive, and potentially life-threatening. The rise in the identification of rare diseases can be attributed to enhanced diagnostic capabilities advancements in genetic testing, imaging, and data analysis have significantly improved the accuracy of diagnosing conditions that were previously undetected or misdiagnosed. Fragile X syndrome (FXS) treatment highlights the significance of government funding by underlining the need for specialized therapies and early interventions, which help to raise awareness and channel resources toward expanded research and medical care. For instance, in February 2024, the UK Parliament's House of Commons Library reported a government commitment of £14 million ($17.3 million) to create a national rare disease research platform, featuring 11 research nodes and a central coordinating hub across the UK. Therefore, government investment in rare diseases is accelerating the growth of the FXS treatment market.
Key players in the fragile X syndrome (FXS) treatment market are prioritizing the development of innovative therapies, such as calcium-activated potassium (BK) channel activators, to address underlying neurological dysfunction and improve treatment outcomes. A BK channel activator enhances the function of potassium channels that control cell excitability and neurotransmitter release. For example, in January 2025, Spinogenix Inc., a US-based biotechnology company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SPG601, a BK channel activator intended for FXS treatment. This designation accelerates clinical development and regulatory approval, bringing this novel therapeutic option designed to address synaptic dysfunction closer to patients. It also reflects the urgent need for effective FXS treatments and the potential of SPG601 to alleviate cognitive and behavioral symptoms by targeting key neurological mechanisms.
In August 2023, Harmony Biosciences Holdings Inc., a US-based commercial-stage pharmaceutical firm, acquired Zynerba Pharmaceuticals for approximately $60 million. This acquisition enables Harmony to diversify its therapeutic offerings and strengthen its pipeline by integrating Zynerba’s lead candidate, Zygel a synthetic cannabidiol gel currently in Phase 3 trials for Fragile X syndrome and Phase 2 trials for 22q11.2 deletion syndrome. Zygel has received both orphan drug and FDA Fast Track designations for Fragile X syndrome. Zynerba Pharmaceuticals Inc. is a US-based biopharma company specializing in the development of transdermal cannabinoid treatments for FXS.
Major companies operating in the fragile x syndrome (fxs) treatment market are F. Hoffmann-La Roche Ltd, Shionogi & Co. Ltd., Marinus Pharmaceuticals Inc., Healx Ltd, Neuren Pharmaceuticals Limited, Fulcrum Therapeutics Inc., Neuronascent Inc., Autifony Therapeutics Limited, Quadrant Biosciences Inc., Neurolixis Inc., Taysha Gene Therapies Inc., Ovid Therapeutics Inc., Spinogenix Inc., Epigen Biosciences Inc., Confluence Pharmaceuticals Inc., Actinogen Medical Limited, Anavex Life Sciences Corp., FRAXA Research Foundation Inc., Zynerba Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Sage Therapeutics Inc., Neurocrine Biosciences Inc., Ionis Pharmaceuticals Inc.
North America was the largest region in the fragile X syndrome FXS treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fragile x syndrome (fxs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fragile x syndrome (fxs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the fragile x syndrome treatment market by increasing costs of imported active pharmaceutical ingredients, diagnostic equipment, laboratory reagents, and specialized medical devices used in research and treatment delivery. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces cost pressure on drug manufacturing inputs. These tariffs are contributing to higher treatment development costs and slower commercialization timelines. However, they are also encouraging domestic drug manufacturing, localized clinical research, and increased investment in regional rare-disease treatment ecosystems.
The fragile x syndrome (fxs) treatment market research report is one of a series of new reports that provides fragile x syndrome (fxs) treatment market statistics, including fragile x syndrome (fxs) treatment industry global market size, regional shares, competitors with a fragile x syndrome (fxs) treatment market share, detailed fragile x syndrome (fxs) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fragile x syndrome (fxs) treatment industry. This fragile x syndrome (fxs) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fragile X Syndrome (FXS) treatment encompasses a combination of medical, therapeutic, and educational strategies aimed at managing symptoms and enhancing the quality of life for individuals affected by this genetic disorder, which leads to intellectual disabilities, behavioral challenges, and developmental delays. Common symptoms include developmental delays, difficulties in social interaction and communication, along with distinct physical features such as an elongated face and prominent ears. Treatment for FXS commonly involves pharmaceutical drugs such as antidepressants, antipsychotics, and stimulants to address behavioral concerns.
The primary treatment approaches for FXS include pharmacological interventions, psychotherapy, and educational and training programs. Pharmacological treatment focuses on using medications to manage symptoms such as anxiety, hyperactivity, and mood disorders, targeting specific neurological and behavioral challenges to improve patient well-being. These medications may be delivered orally, via injections, or through topical applications. Related conditions include Fragile X Syndrome, Fragile X Mental Retardation 1 (FMR1)-related primary ovarian insufficiency, Fragile X-linked Fragile E (XE) syndrome, Renpenning syndrome, and other associated disorders. Treatments are applied across all age groups - children, adults, and the elderly and are generally provided in hospitals, specialized clinics, and various healthcare facilities.
The fragile x syndrome (FXS) treatment market consists of sales of genetic testing services, gene therapies, and behavioral intervention program. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The fragile x syndrome (fxs) treatment market size is expected to see strong growth in the next few years. It will grow to $3 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing investments in precision medicine research, expansion of gene-targeted therapies, rising clinical trial activity for rare diseases, growing focus on early genetic screening, increasing collaboration between biotech firms and research institutions. Major trends in the forecast period include increasing focus on targeted pharmacological therapies, growing integration of behavioral and drug-based treatments, expansion of personalized treatment approaches, rising adoption of early diagnosis and intervention programs, enhanced development of novel mglur5 and gaba-based therapies.
Government initiatives and funding for rare diseases are expected to drive the expansion of the fragile X syndrome (FXS) treatment market in the near future. Rare diseases are medical conditions that impact a small fraction of the population and are often chronic, progressive, and potentially life-threatening. The rise in the identification of rare diseases can be attributed to enhanced diagnostic capabilities advancements in genetic testing, imaging, and data analysis have significantly improved the accuracy of diagnosing conditions that were previously undetected or misdiagnosed. Fragile X syndrome (FXS) treatment highlights the significance of government funding by underlining the need for specialized therapies and early interventions, which help to raise awareness and channel resources toward expanded research and medical care. For instance, in February 2024, the UK Parliament's House of Commons Library reported a government commitment of £14 million ($17.3 million) to create a national rare disease research platform, featuring 11 research nodes and a central coordinating hub across the UK. Therefore, government investment in rare diseases is accelerating the growth of the FXS treatment market.
Key players in the fragile X syndrome (FXS) treatment market are prioritizing the development of innovative therapies, such as calcium-activated potassium (BK) channel activators, to address underlying neurological dysfunction and improve treatment outcomes. A BK channel activator enhances the function of potassium channels that control cell excitability and neurotransmitter release. For example, in January 2025, Spinogenix Inc., a US-based biotechnology company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SPG601, a BK channel activator intended for FXS treatment. This designation accelerates clinical development and regulatory approval, bringing this novel therapeutic option designed to address synaptic dysfunction closer to patients. It also reflects the urgent need for effective FXS treatments and the potential of SPG601 to alleviate cognitive and behavioral symptoms by targeting key neurological mechanisms.
In August 2023, Harmony Biosciences Holdings Inc., a US-based commercial-stage pharmaceutical firm, acquired Zynerba Pharmaceuticals for approximately $60 million. This acquisition enables Harmony to diversify its therapeutic offerings and strengthen its pipeline by integrating Zynerba’s lead candidate, Zygel a synthetic cannabidiol gel currently in Phase 3 trials for Fragile X syndrome and Phase 2 trials for 22q11.2 deletion syndrome. Zygel has received both orphan drug and FDA Fast Track designations for Fragile X syndrome. Zynerba Pharmaceuticals Inc. is a US-based biopharma company specializing in the development of transdermal cannabinoid treatments for FXS.
Major companies operating in the fragile x syndrome (fxs) treatment market are F. Hoffmann-La Roche Ltd, Shionogi & Co. Ltd., Marinus Pharmaceuticals Inc., Healx Ltd, Neuren Pharmaceuticals Limited, Fulcrum Therapeutics Inc., Neuronascent Inc., Autifony Therapeutics Limited, Quadrant Biosciences Inc., Neurolixis Inc., Taysha Gene Therapies Inc., Ovid Therapeutics Inc., Spinogenix Inc., Epigen Biosciences Inc., Confluence Pharmaceuticals Inc., Actinogen Medical Limited, Anavex Life Sciences Corp., FRAXA Research Foundation Inc., Zynerba Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Sage Therapeutics Inc., Neurocrine Biosciences Inc., Ionis Pharmaceuticals Inc.
North America was the largest region in the fragile X syndrome FXS treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fragile x syndrome (fxs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fragile x syndrome (fxs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the fragile x syndrome treatment market by increasing costs of imported active pharmaceutical ingredients, diagnostic equipment, laboratory reagents, and specialized medical devices used in research and treatment delivery. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces cost pressure on drug manufacturing inputs. These tariffs are contributing to higher treatment development costs and slower commercialization timelines. However, they are also encouraging domestic drug manufacturing, localized clinical research, and increased investment in regional rare-disease treatment ecosystems.
The fragile x syndrome (fxs) treatment market research report is one of a series of new reports that provides fragile x syndrome (fxs) treatment market statistics, including fragile x syndrome (fxs) treatment industry global market size, regional shares, competitors with a fragile x syndrome (fxs) treatment market share, detailed fragile x syndrome (fxs) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fragile x syndrome (fxs) treatment industry. This fragile x syndrome (fxs) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fragile X Syndrome (FXS) treatment encompasses a combination of medical, therapeutic, and educational strategies aimed at managing symptoms and enhancing the quality of life for individuals affected by this genetic disorder, which leads to intellectual disabilities, behavioral challenges, and developmental delays. Common symptoms include developmental delays, difficulties in social interaction and communication, along with distinct physical features such as an elongated face and prominent ears. Treatment for FXS commonly involves pharmaceutical drugs such as antidepressants, antipsychotics, and stimulants to address behavioral concerns.
The primary treatment approaches for FXS include pharmacological interventions, psychotherapy, and educational and training programs. Pharmacological treatment focuses on using medications to manage symptoms such as anxiety, hyperactivity, and mood disorders, targeting specific neurological and behavioral challenges to improve patient well-being. These medications may be delivered orally, via injections, or through topical applications. Related conditions include Fragile X Syndrome, Fragile X Mental Retardation 1 (FMR1)-related primary ovarian insufficiency, Fragile X-linked Fragile E (XE) syndrome, Renpenning syndrome, and other associated disorders. Treatments are applied across all age groups - children, adults, and the elderly and are generally provided in hospitals, specialized clinics, and various healthcare facilities.
The fragile x syndrome (FXS) treatment market consists of sales of genetic testing services, gene therapies, and behavioral intervention program. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Fragile X Syndrome (FXS) Treatment Market Characteristics
3. Fragile X Syndrome (FXS) Treatment Market Supply Chain Analysis
4. Global Fragile X Syndrome (FXS) Treatment Market Trends and Strategies
5. Fragile X Syndrome (FXS) Treatment Market Analysis of End Use Industries
7. Global Fragile X Syndrome (FXS) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Fragile X Syndrome (FXS) Treatment Total Addressable Market (TAM) Analysis for the Market
9. Fragile X Syndrome (FXS) Treatment Market Segmentation
10. Fragile X Syndrome (FXS) Treatment Market Regional and Country Analysis
11. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market
12. China Fragile X Syndrome (FXS) Treatment Market
13. India Fragile X Syndrome (FXS) Treatment Market
14. Japan Fragile X Syndrome (FXS) Treatment Market
15. Australia Fragile X Syndrome (FXS) Treatment Market
16. Indonesia Fragile X Syndrome (FXS) Treatment Market
17. South Korea Fragile X Syndrome (FXS) Treatment Market
18. Taiwan Fragile X Syndrome (FXS) Treatment Market
19. South East Asia Fragile X Syndrome (FXS) Treatment Market
20. Western Europe Fragile X Syndrome (FXS) Treatment Market
21. UK Fragile X Syndrome (FXS) Treatment Market
22. Germany Fragile X Syndrome (FXS) Treatment Market
23. France Fragile X Syndrome (FXS) Treatment Market
24. Italy Fragile X Syndrome (FXS) Treatment Market
25. Spain Fragile X Syndrome (FXS) Treatment Market
26. Eastern Europe Fragile X Syndrome (FXS) Treatment Market
27. Russia Fragile X Syndrome (FXS) Treatment Market
28. North America Fragile X Syndrome (FXS) Treatment Market
29. USA Fragile X Syndrome (FXS) Treatment Market
30. Canada Fragile X Syndrome (FXS) Treatment Market
31. South America Fragile X Syndrome (FXS) Treatment Market
32. Brazil Fragile X Syndrome (FXS) Treatment Market
33. Middle East Fragile X Syndrome (FXS) Treatment Market
34. Africa Fragile X Syndrome (FXS) Treatment Market
36. Fragile X Syndrome (FXS) Treatment Market Competitive Landscape and Company Profiles
37. Fragile X Syndrome (FXS) Treatment Market Other Major and Innovative Companies
40. Fragile X Syndrome (FXS) Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Fragile X Syndrome (FXS) Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses fragile x syndrome (fxs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fragile x syndrome (fxs) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fragile x syndrome (fxs) treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Type: Pharmacological Treatment; Psychotherapy; Education And Training2) By Route of Administration: Oral; Injectable; Intranasal And Transdermal Delivery Routes
3) By Related Disorder: Fragile X Syndrome; Fragile X Mental Retardation 1 (FMR1)-Related Primary Ovarian Insufficiency; Fragile X-Associated Tremor; Fragile X-Associated Neuropsychiatric Disorders; Other Related Disorders
4) By Patient Age Group: Children; Adults; Elderly
5) By End-User: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Pharmacological Treatment: Antidepressants; Antipsychotics; Stimulants; Anticonvulsants; Anti-Anxiety Medications; mGluR5 Antagonists (Metabotropic Glutamate Receptor 5 Antagonists); GABA Agonists (Gamma-Aminobutyric Acid Agonists)2) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Family Therapy; Social Skills Training; Occupational Therapy; Speech And Language Therapy; Applied Behavior Analysis (ABA)
3) By Education And Training: Special Education Programs; Individualized Education Programs (IEPs); Parent Training And Support; Behavioral Intervention Plans; Skill-Building Workshops; Inclusive Classroom Strategies
Companies Mentioned: F. Hoffmann-La Roche Ltd; Shionogi & Co. Ltd.; Marinus Pharmaceuticals Inc.; Healx Ltd; Neuren Pharmaceuticals Limited; Fulcrum Therapeutics Inc.; Neuronascent Inc.; Autifony Therapeutics Limited; Quadrant Biosciences Inc.; Neurolixis Inc.; Taysha Gene Therapies Inc.; Ovid Therapeutics Inc.; Spinogenix Inc.; Epigen Biosciences Inc.; Confluence Pharmaceuticals Inc.; Actinogen Medical Limited; Anavex Life Sciences Corp.; FRAXA Research Foundation Inc.; Zynerba Pharmaceuticals Inc.; BioMarin Pharmaceutical Inc.; PTC Therapeutics Inc.; Sage Therapeutics Inc.; Neurocrine Biosciences Inc.; Ionis Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Fragile X Syndrome (FXS) Treatment market report include:- F. Hoffmann-La Roche Ltd
- Shionogi & Co. Ltd.
- Marinus Pharmaceuticals Inc.
- Healx Ltd
- Neuren Pharmaceuticals Limited
- Fulcrum Therapeutics Inc.
- Neuronascent Inc.
- Autifony Therapeutics Limited
- Quadrant Biosciences Inc.
- Neurolixis Inc.
- Taysha Gene Therapies Inc.
- Ovid Therapeutics Inc.
- Spinogenix Inc.
- Epigen Biosciences Inc.
- Confluence Pharmaceuticals Inc.
- Actinogen Medical Limited
- Anavex Life Sciences Corp.
- FRAXA Research Foundation Inc.
- Zynerba Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- PTC Therapeutics Inc.
- Sage Therapeutics Inc.
- Neurocrine Biosciences Inc.
- Ionis Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.23 Billion |
| Forecasted Market Value ( USD | $ 3 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
